Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Marizyme Inc (OP: MRZM ) 0.0320 UNCHANGED Last Price Updated: 9:46 AM EDT, Aug 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 0.0320 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0320 Today's Range 0.0320 - 0.0320 52wk Range 0.0313 - 0.4050 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft May 06, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Marizyme, Inc. Secures FDA 510(k) Clearance for Controlled Room Temperature Storage DuraGraft May 06, 2024 JUPITER, FL - (NewMediaWire) - May 06, 2024 - Marizyme, Inc. (OTCQB: MRZM) is pleased to announce that its flagship product DuraGraft® will no longer require refrigerated storage and will be able to be... Via TheNewswire.com Topics Economy Exposures Product Safety Supply Chain Performance YTD -74.42% -74.42% 1 Month +2.24% +2.24% 3 Month -65.59% -65.59% 6 Month -54.29% -54.29% 1 Year -68.00% -68.00% More News Read More Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM) April 16, 2024 Via NewMediaWire Exposures Product Safety Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM) April 16, 2024 Via TheNewswire.com Exposures Product Safety Marizyme CEO Delivers Business Update October 23, 2023 Via NewMediaWire Exposures Product Safety InvestmentPitch Media Video Features Marizyme's CEO David Barthel Discussing Receipt of FDA Clearance for its Flagship DuraGraft Medical Device October 13, 2023 Via ACCESSWIRE The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News October 06, 2023 Via ACCESSWIRE Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft October 06, 2023 Via NewMediaWire Exposures Product Safety Marizyme (OTCQB: MRZM) Announces IP Developments for DuraGraft and Its Pipeline Products May 10, 2023 Via Spotlight Growth Topics Intellectual Property Exposures Intellectual Property Marizyme Announces IP Developments for DuraGraft and Its Pipeline Products May 10, 2023 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Marizyme (OTCQB: MRZM) CEO Delivers Business Update May 03, 2023 Via Spotlight Growth Exposures Product Safety Marizyme CEO Delivers Business Update May 03, 2023 Via NewMediaWire Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office January 05, 2022 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Product Safety Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing December 23, 2021 Via NewMediaWire Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress December 03, 2021 Via NewMediaWire Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories December 03, 2021 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Marizyme is Pleased to Announce the Appointment of David Barthel as CEO November 16, 2021 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.